Evaluation of Enzyme Inhibitors in Drug Discovery - Robert A. Copeland. Librería Servicio Médico / Libro Dental / Lib...

Está en... Inicio > Medicina > Farmacología > Farmacología > Evaluation of Enzyme Inhibitors in Drug Discovery - Robert A. Copeland

Evaluation of Enzyme Inhibitors in Drug Discovery - Robert A. Copeland

Descripción

Author : Robert A. Copeland Language: English Finishing : Hardcover, 572 pages ISBN : 978-1-118-48813-3 Edition Number: 2/2013 Author Information: ROBERT A. COPELAND, PhD, is Executive Vice President and Chief Scientific Officer at Epizyme, Inc., a biopharmaceutical company in Cambridge, Massachusetts. He is on the Editorial Board of The Journal of Biological Chemistry and a member of the Faculty of...

Ver descripción completa

Medicina

Descripción completa de: Evaluation of Enzyme Inhibitors in Drug Discovery - Robert A. Copeland

Author : Robert A. Copeland

Language: English

Finishing : Hardcover, 572 pages

ISBN : 978-1-118-48813-3

Edition Number: 2/2013

Author Information:

ROBERT A. COPELAND, PhD, is Executive Vice President and Chief Scientific Officer at Epizyme, Inc., a biopharmaceutical company in Cambridge, Massachusetts. He is on the Editorial Board of The Journal of Biological Chemistry and a member of the Faculty of 1000. Dr. Copeland has contributed more than 175 publications to the scientific literature and holds eight U.S.-issued patents. He has authored several books in protein science and enzymology, including Enzymes: A Practical Introduction to Structure, Mechanism, and Data Analysis, Second Edition(Wiley).

Description:

Offers essential guidance for discovering and optimizing novel drug therapies

Using detailed examples, Evaluation of Enzyme Inhibitors in Drug Discovery equips researchers with the tools needed to apply the science of enzymology and biochemistry to the discovery, optimization, and preclinical development of drugs that work by inhibiting specific enzyme targets. Readers will applaud this book for its clear and practical presentations, including its expert advice on best practices to follow and pitfalls to avoid.

This Second Edition brings the book thoroughly up to date with the latest research findings and practices. Updates explore additional forms of enzyme inhibition and special treatments for enzymes that act on macromolecular substrates. Readers will also find new discussions detailing the development and application of the concept of drug-target residence time.

Evaluation of Enzyme Inhibitors in Drug Discovery begins by explaining why enzymes are such important drug targets and then examines enzyme reaction mechanisms. The book covers:

Reversible modes of inhibitor interactions with enzymes
Assay considerations for compound library screening
Lead optimization and structure-activity relationships for reversible inhibitors
Slow binding and tight binding inhibitors
Drug-target residence time
Irreversible enzyme inactivators

The book ends with a new chapter exploring the application of quantitative biochemical principles to the pharmacologic evaluation of drug candidates during lead optimization and preclinical development.

The Second Edition of Evaluation of Enzyme Inhibitors in Drug Discovery continues to offer a treatment of enzymology applied to drug discovery that is quantitative and mathematically rigorous. At the same time, the clear and simple presentations demystify the complex science of enzymology, making the book accessible to many fields— from pharmacology to medicinal chemistry to biophysics to clinical medicine.

Table Of Contents:

FOREWORD TO SECOND EDITION BY CHRISTOPHER T. WALSH xvii
PREFACE TO SECOND EDITION xix
FOREWORD TO FIRST EDITION BY PAUL S. ANDERSON xxiii
PREFACE TO FIRST EDITION xxv
ACKNOWLEDGMENTS FROM FIRST EDITION xxix
1. WHY ENZYMES AS DRUG TARGETS? 1
Key Learning Points 1
1.1 Enzymes Are Essential for Life 2
1.2 Enzyme Structure and Catalysis 6
1.3 Permutations of Enzyme Structure During Catalysis 12
1.4 Extension to Other Target Classes 17
1.5 Other Reasons for Studying Enzymes 18
1.6 Summary 21
References 22
2. ENZYME REACTION MECHANISMS 25
Key Learning Points 25
2.1 Initial Binding of Substrate 25
2.2 Noncovalent Forces in Reversible Ligand Binding to Enzymes 28
2.2.1 Electrostatic Forces 28
2.2.2 Hydrogen Bonds 28
2.2.3 Hydrophobic Forces 29
2.2.4 Van der Waals Forces 30
2.3 Transformations of the Bound Substrate 30
2.3.1 Strategies for Transition State Stabilization 32
2.3.2 Enzyme Active Sites Are Most Complementary to the Transition State Structure 36
2.4 Steady State Analysis of Enzyme Kinetics 39
2.4.1 Factors Affecting the Steady State Kinetic Constants 43
2.5 Typical Values of Steady State Kinetic Parameters 46
2.6 Graphical Determination of kcat and KM 47
2.7 Reactions Involving Multiple Substrates 49
2.7.1 Bisubstrate Reaction Mechanisms 49
2.8 Summary 54
References 54
3. REVERSIBLE MODES OF INHIBITOR INTERACTIONS WITH ENZYMES 57
Key Learning Points 57
3.1 Enzyme–Inhibitor Binding Equilibria 58
3.2 Competitive Inhibition 59
3.3 Noncompetitive Inhibition 68
3.3.1 Mutual Exclusivity Studies 76
3.3.2 Noncompetitive Inhibition by Active Site-Directed Inhibitors 80
3.4 Uncompetitive Inhibition 82
3.5 Inhibition Modality in Bisubstrate Reactions 86
3.6 Value of Knowing Inhibitor Modality 88
3.6.1 Quantitative Comparisons of Inhibitor Affinity 88
3.6.2 Relating Ki to Binding Energy 89
3.6.3 Defi ning Target Selectivity by Ki Values 92
3.6.4 Potential Advantages and Disadvantages of Different Inhibition Modalities in Vivo 92
3.6.5 Knowing Inhibition Modality Is Important for Structure-Based Lead Optimization 95
3.7 Enzyme Reactions on Macromolecular Substrates 96
3.7.1 Challenges in Inhibiting Protein-Protein Interactions 97
3.7.2 Hot Spots in Protein–Protein Interactions 99
3.7.3 Factors Affecting Protein–Protein Interactions 104
3.7.4 Separation of Binding and Catalytic Recognition Elements 107
3.7.5 Noncompetitive Inhibition by Active Site-Binding Molecules for Exosite Utilizing Enzymes 109
3.7.6 Processive and Distributive Mechanisms of Catalysis 110
3.7.7 Effect of Substrate Conformation on Enzyme Kinetics 116
3.7.8 Inhibitor Binding to Substrates 116
3.8 Summary 118
References 119
4. ASSAY CONSIDERATIONS FOR COMPOUND LIBRARY SCREENING 123
Key Learning Points 123
4.1 Measures of Assay Performance 125
4.1.1 Calibration Curves 125
4.1.2 Total, Background, and Specific Signal 128
4.1.3 Defining Inhibition, Signal Robustness, and Hit Criteria 130
4.2 Measuring Initial Velocity 133
4.2.1 End-Point and Kinetic Readouts 135
4.2.2 Effect of Enzyme Concentration 137
4.2.3 Other Factors Affecting Initial Velocity 139
4.3 Balanced Assay Conditions 142
4.3.1 Balancing Conditions for Multisubstrate Reactions 145
4.4 Order of Reagent Addition 146
4.5 Use of Natural Substrates and Enzymes 148
4.6 Coupled Enzyme Assays 154
4.7 Hit Validation 156
4.7.1 Determination of Hit Reproducibility 156
4.7.2 Verification of Chemical Purity and Structure 158
4.7.3 Hit Verification in Orthogonal Assays 159
4.7.4 Chemical and Pharmacological Tractability 160
4.7.5 Promiscuous Inhibitors 162
4.7.6 Prioritization of Confirmed Hits 164
4.7.7 Hit Expansion 165
4.8 Summary 166
References 166
5. LEAD OPTIMIZATION AND STRUCTURE–ACTIVITY RELATIONSHIPS FOR REVERSIBLE INHIBITORS 169
Key Learning Points 169
5.1 Concentration–Response Plots and IC50 Determination 170
5.1.1 The Hill Coefficient 176
5.1.2 Graphing and Reporting Concentration–Response Data 180
5.2 Testing for Reversibility 183
5.3 Determining Reversible Inhibition Modality and Dissociation Constant 188
5.4 Comparing Relative Affinity 190
5.4.1 Compound Selectivity 192
5.5 Associating Cellular Effects with Target Enzyme Inhibition 193
5.5.1 Cellular Phenotype Should Be Consistent with Genetic Knockout or Knockdown of the Target Enzyme
194
5.5.2 Cellular Activity Should Require a Certain Affinity for the Target Enzyme 194
5.5.3 Buildup of Substrate andor Diminution of Product for the Target Enzyme Should Be Observed in Cells
197
5.5.4 Cellular Phenotype Should Be Reversed by Cell-Permeable Product or Downstream Metabolites of the
Target Enzyme Activity 198
5.5.5 Mutation of the Target Enzyme Should Lead to Resistance or Hypersensitivity to Inhibitors 199
5.6 Summary 200
References 200
6. SLOW BINDING INHIBITORS 203
Key Learning Points 203
6.1 Determining kobs: The Rate Constant for Onset of Inhibition 205
6.2 Mechanisms of Slow Binding Inhibition 207
6.3 Determination of Mechanism and Assessment of True Affinity 210
6.3.1 Potential Clincial Advantages of Slow Off-Rate Inhibitors 217
6.4 Determining Inhibition Modality for Slow Binding Inhibitors 217
6.5 SAR for Slow Binding Inhibitors 219
6.6 Some Examples of Pharmacologically Interesting Slow Binding Inhibitors 220
6.6.1 Examples of Scheme B: Inhibitors of Zinc Peptidases and Proteases 220
6.6.2 Example of Scheme C: Inhibition of Dihydrofolate Reductase by Methotrexate 226
6.6.3 Example of Scheme C: Inhibition of Calcineurin by FKBP-Inhibitor Complexes 229
6.6.4 Example of Scheme C When Ki Ki * << : Aspartyl Protease Inhibitors 231
6.6.5 Example of Scheme C When k6 Is Very Small: Selective COX2 Inhibitors 234
6.7 Summary 242
References 243
7. TIGHT BINDING INHIBITION 245
Key Learning Points 245
7.1 Effects of Tight Binding Inhibition on Concentration–Response Data 246
7.2 The IC50 Value Depends on Ki app and [E]T 248
7.3 Morrison’s Quadratic Equation for Fitting Concentration–Response Data for Tight Binding Inhibitors 253
7.3.1 Optimizing Conditions for Ki app Determination Using Morrison’s Equation 255
7.3.2 Limits on Ki app Determinations 256
7.3.3 Use of a Cubic Equation When Both Substrate and Inhibitor Are Tight Binding 257
7.4 Determining Modality for Tight Binding Enzyme Inhibitors 258
7.5 Tight Binding Inhibitors Often Display Slow Binding Behavior 261
7.6 Practical Approaches to Overcoming the Tight Binding Limit in Determining Ki 263
7.7 Enzyme-Reaction Intermediate Analogues as Examples of Tight Binding Inhibitors 266
7.7.1 Bisubstrate Analogues 271
7.7.2 Testing for Transition State Mimicry 272
7.8 Potential Clinical Advantages of Tight Binding Inhibitors 277
7.9 Determination of [E]T Using Tight Binding Inhibitors 279
7.10 Summary 282
References 282
8. DRUG–TARGET RESIDENCE TIME 287
Key Learning Points 287
8.1 Open and Closed Systems in Biology 288
8.2 The Static View of Drug–Target Interactions 292
8.3 Conformational Adaptation in Drug–Target Interactions 294
8.3.1 Conformational Selection Model 294
8.3.2 Induced-Fit Model 296
8.3.3 Kinetic Distinction Between Conformational Selection and Induced-Fit Mechanisms 297
8.4 Impact of Residence Time on Natural Receptor–Ligand Function 300
8.4.1 Immune Response 300
8.4.2 Control of Protease Activity by Natural Inhibitors 302
8.5 Impact of Drug–Target Residence Time on Drug Action 304
8.5.1 Mathematical Defi nition of Residence Time for Different Mechanisms of Drug–Target Interaction 304
8.5.2 Impact of Residence Time on Cellular Activity 305
8.5.3 Impact on Effi cacy and Duration in Vivo 309
8.5.4 Temporal Target Selectivity and Drug Safety 316
8.6 Experimental Measures of Drug–Target Residence Time 318
8.6.1 Kinetic Analysis of Approach to Equilibrium 318
8.6.2 Jump-Dilution Experiments 319
8.6.3 Separation Methods 321
8.6.4 Spectroscopic Differentiation 322
8.6.5 Immobilized Binding Partner Methods 324
8.7 Drug–Target Residence Time Structure–Activity Relationships 325
8.7.1 Structural Changes Associated with Conformational Adaptation 326
8.7.2 Thermodynamics of Drug–Target Complex Dissociation 328
8.7.3 A Retrograded Induced-Fit Model of Drug–Target Complex Dissociation 332
8.8 Recent Applications of the Residence Time Concept 334
8.9 Limitations of Drug–Target Residence Time 338
8.10 Summary 340
References 341
9. IRREVERSIBLE ENZYME INACTIVATORS 345
Key Learning Points 345
9.1 Kinetic Evaluation of Irreversible Enzyme Inactivators 346
9.2 Affinity Labels 350
9.2.1 Quiescent Affinity Labels 351
9.2.2 Potential Liabilities of Affinity Labels as Drugs 356
9.3 Mechanism-Based Inactivators 358
9.3.1 Distinguishing Features of Mechanism-Based Inactivation 360
9.3.2 Determination of the Partition Ratio 366
9.3.3 Potential Clinical Advantages of Mechanism-Based Inactivators 367
9.3.4 Examples of Mechanism-Based Inactivators as Drugs 368
9.4 Use of Affi nity Labels as Mechanistic Tools 375
9.5 Summary 380
References 380
10. QUANTITATIVE BIOCHEMISTRY IN THE PHARMACOLOGICAL EVALUATION OF DRUGS 383
Key Learning Points 383
10.1 In Vitro ADMET Properties 384
10.1.1 Exponential Decay Processes and the Definition of Half-Life 385
10.1.2 Caco-2 Cell Permeability as a Surrogate for Intestinal Absorption 387
10.1.3 Whole Blood or Plasma Stability 390
10.1.4 Plasma Protein Binding 392
10.1.5 Metabolism of Xenobiotics in the Liver 397
10.1.6 Hepatocyte, S9, and Microsome Stability 400
10.1.7 CYP450 Mediated Metabolism 403
10.1.8 Cytochrome P450 Inhibition 408
10.1.9 hERG Inhibition 416
10.2 In Vivo Pharmacokinetic Studies 426
10.2.1 General Considerations and Curve Fitting Parameters 426
10.2.2 Kinetic Models of Drug PK 432
10.2.3 Absorption and Bioavailability 444
10.2.4 Factors Affecting PK Parameters 445
10.2.5 Allometric Scaling of Drug Pharmacokinetics 451
10.3 Metabolite Identification 453
10.4 Measures of Target Occupancy 454
10.4.1 Radiometric Imaging 455
10.4.2 Ex Vivo Determination of Target Occupancy 457
10.4.3 Pharmacodynamic Measures of Target Engagement 459
10.5 Summary 465
References 466
APPENDIX 1 KINETICS OF BIOCHEMICAL REACTIONS 471
A1.1 The Law of Mass Action and Reaction Order 471
A1.2 First-Order Reaction Kinetics 475
A1.3 Second-Order Reaction Kinetics 478
A1.4 Pseudo–First-Order Reaction Conditions 479
A1.5 Approach to Equilibrium: An Example of the Kinetics of Reversible Reactions 480
APPENDIX 2 DERIVATION OF THE ENZYME–LIGAND BINDING ISOTHERM EQUATION 483
APPENDIX 3 SERIAL DILUTION SCHEMES 487
APPENDIX 4 RELATIONSHIP BETWEEN [I ]IC50 AND PERCENTAGE INHIBITION OF ENZYME ACTIVITY WHEN
h = 1 491
APPENDIX 5 PROPAGATION OF UNCERTAINTIES IN EXPERIMENTAL MEASUREMENTS 493
A5.1 Uncertainty Propagation for Addition or Subtraction of Two Experimental Parameters 493
A5.2 Uncertainty Propagation for Multiplication or Division of Two Experimental Parameters 494
A5.3 Uncertainty Propagation for Multiplication or Division of an Experimental Parameter by A Constant 494
A5.4 Uncertainty Propagation for an Experimental Parameter Raised by an Exponent 494
A5.5 Uncertainty Propagation for a General Function of Experimental Parameters 494
Reference 495
APPENDIX 6 USEFUL PHYSICAL CONSTANTS AT DIFFERENT TEMPERATURES 497
APPENDIX 7 COMMON RADIOACTIVE ISOTOPES USED IN STUDIES OF ENZYMES 499
APPENDIX 8 COMMON PREFIXES FOR UNITS IN BIOCHEMISTRY 501
APPENDIX 9 SOME AROMATIC RING SYSTEMS COMMONLY FOUND IN DRUGS 503
APPENDIX 10 RESIDUAL PLOTS 505
INDEX 509

See Less

Puedes encontrar este libro tambien en las siguientes categorías

Farmacología

Valoración:

¡Sea el primero en dejar un comentario!

Nuevo Comentario

Subir